Cigna implemented a positive coverage policy for Intrinsic Therapeutics' Barricaid bone-anchored annular closure device, the medtech company said June 21.
Barricaid is designed to prevent reherniation and reoperation for patients with large annular defects after lumbar discectomy, according to a news release. It has been used in more than 10,000 patients and is supported by clinical studies.
"This new coverage policy will give Cigna members access to the Barricaid technology and help to reduce the burden of reherniation and reoperation for discectomy patients when deemed medically necessary by their surgeo," Intrinsic Therapeutics founder Greg Lambrecht said in the release.
The new Cigna policy went into effect June 15.